Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

106 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement.
Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Muehlhofer E, Dierig C, Misselwitz F, Kälebo P; ODIXa-HIP Study Investigators. Eriksson BI, et al. Among authors: misselwitz f. Circulation. 2006 Nov 28;114(22):2374-81. doi: 10.1161/CIRCULATIONAHA.106.642074. Epub 2006 Nov 20. Circulation. 2006. PMID: 17116766 Clinical Trial.
Differential effects of clivarin and heparin in patients undergoing hip and knee surgery for the generation of anti-heparin-platelet factor 4 antibodies.
Ahmad S, Haas S, Hoppensteadt DA, Lietz H, Reid U, Bender N, Messmore HL, Misselwitz F, Bacher P, Gaikwad BS, Jeske WP, Walenga JM, Fareed J. Ahmad S, et al. Among authors: misselwitz f. Thromb Res. 2002 Oct 1;108(1):49-55. doi: 10.1016/s0049-3848(02)00397-3. Thromb Res. 2002. PMID: 12586132 Clinical Trial.
BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study.
Turpie AG, Fisher WD, Bauer KA, Kwong LM, Irwin MW, Kälebo P, Misselwitz F, Gent M; OdiXa-Knee Study Group. Turpie AG, et al. Among authors: misselwitz f. J Thromb Haemost. 2005 Nov;3(11):2479-86. doi: 10.1111/j.1538-7836.2005.01602.x. J Thromb Haemost. 2005. PMID: 16241946 Free article. Clinical Trial.
Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement.
Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Misselwitz F, Muehlhofer E, Kälebo P. Eriksson BI, et al. Among authors: misselwitz f. Thromb Res. 2007;120(5):685-93. doi: 10.1016/j.thromres.2006.12.025. Epub 2007 Feb 12. Thromb Res. 2007. PMID: 17292948 Clinical Trial.
Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study.
Agnelli G, Gallus A, Goldhaber SZ, Haas S, Huisman MV, Hull RD, Kakkar AK, Misselwitz F, Schellong S; ODIXa-DVT Study Investigators. Agnelli G, et al. Among authors: misselwitz f. Circulation. 2007 Jul 10;116(2):180-7. doi: 10.1161/CIRCULATIONAHA.106.668020. Epub 2007 Jun 18. Circulation. 2007. PMID: 17576867 Clinical Trial.
106 results